The efficacy of the EpiVacCorona vaccine, registered in Russia on October 13, was verified through the results of the first and second phase of clinical trials
| 01/19/2021 | ionicons-v5-c07: 54 | Camacho Light |
RUSSIA.- The efficacy of the vaccine against Covid-19 EpiVacCorona, developed by the Russian scientific center for virology and biotechnology Véktor, is 100 percent, as announced by the press service of the health agency of Russia, Rospotrebnadzor.
According to the information, the efficacy of the vaccine was verified through the results of the first and second phase of clinical trials.
« The efficacy of the vaccine consists of its immunological and preventive efficacy. According to the results of the first and second phase of clinical trials, the immunological efficacy of the EpiVacCorona vaccine is 100 percent, » the agency indicated.
The second russian vaccine
EpiVacCorona It was registered in mid-October and in November the Russian Health Ministry authorized the Véktor center to carry out clinical trials on up to 3,000 volunteers and on people over 60, according to information from RT.
In early December, the Russian health authorities handed over to the World Health Organization (WHO) documents on EpiVacCorona for your test.
The vaccine EpiVacCorona, which is based on peptide antigens, guarantees immunity against the coronavirus a month after the first injection, announced the Véktor center announced in late November.
The creators of the drug point out that the inoculation of the vaccine in asymptomatic patients of covid-19 does not carry health risks. They also add that they estimate that the injection could be beneficial for some of these patients, as well as it could be useless for others, but in no case would it harm health.